Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia

Atherosclerosis

Volumn 138, Issue 1, 1998, Pages 217-225

  Durrington, P N ^a   Mackness, M I ^a   Bhatnagar, D ^a   Julier, K ^a   Prais, H ^a   Arrol, S ^a   Morgan, J ^a   Wood, G N I ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Bezafibrate; Cholesteryl ester transfer protein; Fibrinogen; Gemfibrozil; Lipoproteins; Paroxonase

Indexed keywords

APOLIPOPROTEIN A1; ARYLESTERASE; BEZAFIBRATE; CHOLESTEROL ESTER TRANSFER PROTEIN; FIBRINOGEN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; HYPERLIPOPROTEINEMIA TYPE 2; LIPOPROTEIN BLOOD LEVEL; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0032076207     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(98)00003-3     Document Type: Article

References (43)

1. Thorp JM, Waring WS Modification of metabolism and distribution of lipids by ethyl chlorophenoxyisobutyrate. Nature. 194:1962;948-949.
2. Staels B, Vu-Dac N, Kosykh VA, Saladin R, Fruchart J-C, Dallongeville J, Auwerx J Fibrates down regulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. J Clin Invest. 95:1995;705-712.
3. Schonfeld G The effects of fibrates on lipoprotein and hemostatic risk factors. Atherosclerosis. 111:1994;161-174.
4. Durrington PN How HDL protects against atheroma. Lancet. 342:1993;1315-1316.
5. Wilhelmsen L, Svardsudd K, Korsan-Bergsten K, Larsson B, Welin L, Tibblin G Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med. 311:1984;501-505.
6. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick park Heart Study. Lancet. 342:1993;1076-1079.
7. Hamsten A, De Faine U, Walldius G, Dahlen G, Szamosi A, Landon C, Blomback M, Wiman B Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 2:1987;3-9.
8. Bradley WA, Booyse FM, Gianturco SH Fibrinolytic and thrombotic factors in atherosclerosis and IHD: the influence of triglyceride-rich lipoproteins (TGRLP). Atherosclerosis. 108 (Suppl):1994;31-39.
9. Winocour PH, Durrington PN, Bhatnagar D, Ishola M, Lalor BC, Arrol S, Anderson DC Double-blind placebo controlled study of the effects of bezafibrate on blood lipids, lipoproteins, and fibrinogen in hyperlipidaemic type I (insulin dependent) diabetes mellitus. Diabetic Med. 7:1990;736-743.
10. Almer L-O, Kjellstrom T The fibrinolytic system and coagulation during bezafibrate treatment of hypertriglyceridemia. Atherosclerosis. 61:1986;81-85.
11. Pazzucconi F, Mannucci L, Mussoni L, Gianfranceschi G, Maderna P, Werba P, Franceschini G, Sirtori CR, Tremoli E Bezafibrate lowers plasma lipids, fibrinogen and platelet aggregability in hypertriglyceridaemia. Eur J Clin Pharmacol. 43:1992;219-223.
12. Avellone G, di Garbo V, Cordova R, Piliego T, Raneli G, De Simone R, Bompiani GD Improvement of fibrinolysis and plasma lipoprotein levels induced by gemfibrozil in hypertriglyceridaemia. Blood Coagul Fibrinolysis. 6:1995;543-548.
13. Branchi A, Rovellini A, Sommariva D, Gugliandolo AG, Fasoli A Effects of three fibrate derivatives and of two HMG CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolaemia. Thromb Haemostas. 70:1993;241-243.
14. Mussoni L, Mannuci I, Sirtori M, Camera M, Maderna P, Sironi L, Tremoli E Hypertriglyceridaemia and regulation of fibrinolytic activity. Arteroscler Thromb. 12:1992;19-27.
15. Ruiz J, Blanche H, James RW, Blatter MC, Charpentier G, Morabia A, Passa P, Froguel P The polymorphism (Gln-Arg 192) of the high-density lipoprotein-bound enzyme paraoxonase is an independent cardiovascular risk factor in non-insulin dependent diabetic patients. Lancet. 346:1995;869-872.
16. Serrato M, Marian AJ A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary heart disease. J Clin Invest. 96:1995;3005-3008.
17. Mackness MI, Arrol S, Durrington PN Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 286:1991;152-154.
18. Mackness MI, Arrol S, Abbott CA, Durrington PN Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis. 104:1993;129-135.
19. Monk JP, Todd PA Bezafibrate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidaemia. Drugs. 33:1987;539-576.
20. Trinder P, Webster D Determination of HDL cholesterol using 2,4,6-tribromo-3-hydroxybenzoic acid with commercial CHOD-PAP reagent. Ann Clin Biochem. 21:1984;430-433.
21. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olsen BJ, Klenk DC Measurement of protein using bicinchoninic acid. Anal Biochem. 150:1985;76-85.
22. Mackness MI, Durrington PN. Lipoprotein analysis for clinical studies. In: Converse CA, Skinner ER, editors. Lipoprotein analysis: a practical approach. Oxford University Press, Oxford 1992:1-42.
23. Stokke KT, Norum KR Determination of lecithin: cholesterol acyltransferase in human blood plasma. Scand J Clin Invest. 27:1971;21-27.
24. Channon KM, Clegg RJ, Bhatnagar D, Ishola M, Arrol S, Durrington PN Investigation of lipid transfer in human serum leading to the development of an isotopic method for the determination of endogenous cholesterol esterification and transfer. Atherosclerosis. 80:1990;217-226.
25. Mackness MI, Harty D, Bhatnagar D, Winocour PH, Arrol S, Ishola M, Durrington PN Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis. 86:1991;193-199.
26. Clauss A Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol. 17:1957;237-246.
27. Shepherd J, Packard CJ, Stewart JM, Atmeh RF, Clark RS, Boag DE, Carr K, Lorimer AR, Ballantyne D, Morgan HG, Morgan H, Veitch Lawrie TD Apolipoprotein A and B (Sf 100-400) metabolism during bezafibrate therapy in hypertriglyceridaemic subjects. J Clin Invest. 74:1984;2164-2177.
28. Caslake MJ, Packard CJ, Gaw A, Murray E, Griffin BA, Vallance BD, Shepherd J Fenofibrate and low density lipoprotein heterogenity in hypercholesterolaemia. Arterioscler Thromb. 13:1993;702-711.
29. Bredie SJH, de Bruin TW, Demacker PNM, Kastelein JJ, Stalenhoef AF Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidaemia and effects on apolipoprotein B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability. Am J Cardiol. 75:1995;348-353.
30. Bhatnagar D, Durrington PN, Channon KM, Prais H, Mackness MI Increased transfer of cholesteryl esters from high density lipoproteins to low density and very low density lipoproteins in patients with angiographic evidence of coronary artery disease. Atherosclerosis. 98:1993;25-32.
31. Bhatnagar D, Durrington PN, Mackness MI, Arrol S, Winocour PH Effects of treatment of hypertriglyceridaemia with gemfibrozil on serum lipoproteins and the transfer of cholesteryl ester from high density lipoproteins to low density lipoproteins. Atherosclerosis. 92:1992;49-57.
32. Kahri J, Vuorinen-Markkola H, Tilly-Kiesi M Effect of gemfibrozil on high density lipoprotein subspecies in non-insulin dependent diabetes mellitus. Relations to lipolytic enzymes and to the cholesteryl ester transfer protein activity. Atherosclerosis. 102:1993;79-89.
33. Homma Y, Ozawa H, Kobayashi T, Yamaguchi H, Sakane H, Mikami Y, Nakamura H Effects of bezafibrate therapy on subfractions of plasma low-density lipoprotein and high-density lipoprotein, and on activities of lecithin: cholesterol acyltransferase and cholesteryl ester transfer protein in patients with hypertriglyceridaemia. Atherosclerosis. 106:1994;191-201.
34. Ponsin G, Girardot G, Berthezene F Mechanism of the gemfibrozil-induced decrease in the transfer of cholesterol esters from high density lipoproteins to very low and low density lipoproteins. Biochem Med Metab Biol. 52:1994;58-64.
35. Mann CJ, Yen FT, Grant AM, Bihain BE Mechanism of plasma cholesteryl ester transfer in hypertriglyceridaemia. J Clin Invest. 88:1991;2059-2063.
36. Homma Y, Ozawa H, Kobayashi T, Yamaguchi H, Sakane H, Mikami Y, Mikaui Y, Nakamura H Effects of bezafibrate therapy on subfractions of plasma low-density lipoprotein and high-density lipoprotein, and on activities of lecithin:cholesterol acyl transferase and cholesteryl ester transfer protein in patients with hyperlipoproteinaemia. Atherosclerosis. 106:1994;191-201.
37. Bagdade JD, Ritter MC, Subbaiah PV Accelerated cholesteryl ester transfer in plasma of patients with hypercholesterolaemia. J Clin Invest. 87:1991;1259-1265.
38. Bruce C, Tall AR Cholesteryl ester transfer proteins, reverse cholesterol transport, and atherosclerosis. Curr Opin Lipidol. 6:1995;306-311.
39. Mackness MI ¬A'-Esterases - Enzymes looking for a role? Biochem Pharmacol. 38:1989;385-390.
40. 2 equilibrium gradient centrifugation: evidence for HDL subpopulations with differing AI/AII molar ratios. J Lipid Res. 20:1979;200-207.
41. Blatter M-C, James RW, Messmer S, Barja F, Pometta D Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-85: Identity of K-85 with paraoxonase. Eur J Biochem. 211:1993;871-879.
42. La Du BN. Human serum paraoxonase/arylesterase. In: Kalow W, editor. Pharmacogenetics of drug metabolism. Pergamon Press, New York. 1992;51-91.
43. Abbott CA, Mackness MI, Kumar S, Boulton AJM, Durrington PN Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol. 15:1995;1812-1818.